文献速递认知障碍与痴呆脑血管病

唐氏综合征患者微出血及其分布与阿尔茨海默病理影像和脑脊液生物标志物的关联

Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome.
PubMed 文献 · Neurology · 2024-07-29

这项横断面研究纳入276例唐氏综合征成人和158例健康整倍体对照,评估微出血的发生、分布及其与阿尔茨海默病生物标志物的关联。唐氏综合征患者微出血更常见(20% vs 8.9%,p<0.001),以幕下和後部脑叶为主,与年龄、APOEε4携带及疾病分期相关;仅海马体积和脑脊液p-tau-181在控制年龄和疾病分期后仍与微出血严重程度相关。

要点

  • 唐氏综合征成人微出血患病率高于健康对照(20% vs 8.9%,p<0.001),且随年龄和AD临床分期增加。
  • 微出血在唐氏综合征患者中主要分布于小脑(33.66%)、颞叶(21.29%)和枕叶(14.85%)。
  • 控制年龄和疾病分期后,仅海马体积(β=-0.18)和脑脊液p-tau-181(β=0.26)与微出血严重程度相关。

核心结论

  • 在唐氏综合征成人中,微出血呈後部脑叶为主分布,与疾病严重程度相关,但不影响认知表现;结果提示AD病理与血管病变存在相互作用,微出血可能是限制该人群使用抗淀粉样蛋白药物的危险因素。

研究设计与样本

  • 横断面研究,纳入来自Down-Alzheimer Barcelona Neuroimaging Initiative和Sant Pau Initiative on Neurodegeneration的276例唐氏综合征成人(≥18岁)和158例健康整倍体对照,均具有T1加权和磁敏感加权图像。

主要发现

  • 唐氏综合征患者微出血发生率高于对照(20% vs 8.9%,p<0.001),严重程度更高(2个及以上微出血:12% vs 1.9%)。
  • 微出血随年龄增加(20-30岁12% vs >60岁60%)和AD临床分期增加(无症状12.42%、前驱期27.9%、痴呆期35.09%)。
  • APOEε4携带者微出血更常见(26% vs 非携带者18.3%,p=0.008),但与血管危险因素无关(p>0.05)。
  • 微出血主要分布于後部:小脑33.66%、颞叶21.29%、枕叶14.85%。
  • 控制年龄和疾病分期后,仅海马体积(标准化β=-0.18 [-0.31, -0.06],p<0.005)和脑脊液p-tau-181浓度(β=0.26 [0.12, 0.41],p<0.005)与微出血严重程度相关;微出血对认知结局影响有限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers. METHODS: This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E (APOE) genotyping; fluid and plasma determinations of beta-amyloid, tau, and neurofilament light; cognitive outcomes (Cambridge Cognitive Examination and modified Cued Recall Test); and vascular risk factors (hypertension, diabetes mellitus, and dyslipidemia). We manually segmented microbleeds and characterized their topography. Associations between microbleed severity and AD biomarkers were explored using between-group comparisons (none vs 1 vs 2+) and multivariate linear models. RESULTS: We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%, p < 0.001), with more severe presentation (12% with 2+ vs 1.9%). Microbleeds increased with age (12% 20-30 years vs 60% > 60 years) and AD clinical stage (12.42% asymptomatic, 27.9% prodromal, 35.09% dementia) were more common in APOEε4 carriers (26% vs 18.3% noncarriers, p = 0.008), but not associated with vascular risk factors (p > 0.05). Microbleeds were predominantly posterior (cerebellum 33.66%; occipital 14.85%; temporal 21.29%) in participants with DS. Associations with microbleed severity were found for neuroimaging and fluid AD biomarkers, but only hippocampal volumes (standardized β = -0.18 [-0.31, -0.06], p < 0.005) and CSF p-tau-181 concentrations (β = 0.26 [0.12, 0.41], p < 0.005) survived regression controlling for age and disease stage, respectively. Microbleeds had limited effect on cognitive outcomes. DISCUSSION: In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zsadanyi SE, Morcillo-Nieto AO, Aranha MR, et al. Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome. Neurology. 2024. PMID: 39074338. doi:10.1212/WNL.0000000000209676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。